Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AZD0305 / AstraZeneca
NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases	Withdrawn	1/2	380	NA	LM-305, Dexamethasone	LaNova Medicines Limited	Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases	12/24	12/25
NCT06106945: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma	Recruiting	1/2	84	Europe, Canada, Japan, US, RoW	AZD0305	AstraZeneca	Multiple Myeloma	11/25	11/25